Zlatareva, Iva
Funding for this research was provided by:
Wellcome Trust (220589/Z/20/Z)
Article History
Received: 26 February 2023
Revised: 6 May 2023
Accepted: 15 May 2023
First Online: 13 June 2023
Competing interests
: IZ is employed on a sponsored research agreement with Takeda Pharmaceutical Company. IZ has provisional patent applications on targeting the BTNL3/8 axis in the human gut. YW consults for PersonGen Biotherapeutics. The authors declare no other competing interests.
: Not applicable.
: Not applicable.